LEXX Profile
Lexaria Bioscience Corp. is a biotechnology company specializing in advanced drug delivery technologies. The company operates through two primary segments: Intellectual Property Licensing and B2B Production. Lexaria is renowned for its proprietary DehydraTECH technology, which significantly enhances the delivery of bioactive compounds. This technology is designed to promote healthier ingestion methods, reduce overall dosing requirements, and improve the effectiveness of active molecule delivery.
The DehydraTECH platform is versatile, applicable to a wide array of active molecules including fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, as well as various cannabinoids. A notable feature of DehydraTECH is its ability to effectively transport drugs across the blood-brain barrier, which is a critical challenge in pharmaceutical delivery. This capability expands the potential applications of Lexaria’s technology to include treatments for central nervous system disorders and other conditions requiring targeted drug delivery.
Lexaria Bioscience operates a fully licensed in-house research laboratory, where it continues to develop and refine its technologies. The company boasts a robust intellectual property portfolio, with 27 patents granted and approximately 50 patents pending worldwide. This extensive patent portfolio underscores the company’s commitment to innovation and protection of its proprietary technologies.
Founded in 2004 and headquartered in Kelowna, Canada, Lexaria Bioscience Corp. is positioned at the forefront of biotechnology advancements. Its focus on improving drug delivery systems through its DehydraTECH technology and its strong intellectual property base illustrate its role in advancing therapeutic efficacy and safety. The company continues to explore new applications for its technology while enhancing its global presence in the biotechnology sector.
|
